当前位置: 首页 >> 检索结果
2221. [Gene therapy and cancer].
Gene therapy by definition aims at modifying the genetic program of a cell towards a therapeutic or prophylactic goal. Several gene therapy strategies for cancer are currently under evaluation: 1) "suicide" gene therapy where an inactive prodrug is converted into a cytotoxic drug; 2) modification of the function of oncogenes and tumor suppressor genes; 3) modification of the host immune response towards the tumor; 4) disruption of the tumor neovascularisation; 5) lysis of tumor cells with replication-competent viruses. Recent results of phase I and II clinical studies have brought great hopes. However, the inefficiency of current gene vectors in infecting targeted cells and their inability to selectively access diseased cells distributed systemically are two major limitations that have to be overcome for further successful clinical applications.
2222. [Summary of the congress].2223. [Prognostic contribution and therapeutic implications of microsatellite instability in colorectal cancer. Role of the pathologist].2224. [Oncogene her-2/neu and ovarian carcinoma: intraperitoneal cellular immunotherapy].2225. [Tools of molecular biology. Diagnostic use of DNA arrays].2226. [Cell cycle and breast cancer].2227. [C cell hyperplasia and medullary microcarcinomas of the thyroid].2228. [Papillary and vesicular carcinoma of the thyroid: diagnostic problems and new data].2229. [Cell cycle, proliferation and stomach cancer].2230. [Deregulation of the cell cycle in bronchial cancers].2231. [Cancer genome or the development of molecular portraits of tumors].
The rapid development of cancer genomics is due to important progresses in oncogenesis, human genome sequencing and emergence of new technologies in genome and transcriptome analysis. In this context, the aim of the French program 'Cartes d'Identites des Tumeurs--Molecular Portraits of Tumors' is to build a public data base containing a pan genome assessment of genome and transcriptome alterations in the major types of tumors as well as in relevant normal cells and experimental models. Data mining is done in the context of genome annotations and clinical and biological informations attached to the enrolled samples. The goal of the program is to define new tests useful for diagnostic procedures in clinical laboratories and new targets for biological treatments of tumors.
2232. [Urothelial tumor and colonic cancer in the context of a syndrome of hereditary predisposition to HNPCC colonic cancer].
作者: A de la Taille.;C Mariette.;M P Buisine.;J Biserte.;J P Triboulet.
来源: Prog Urol. 2000年10卷6期1204-7页
The authors report the association of ureteric tumour and colon carcinomas in the context of hereditary predisposition to HNPCC colon cancer (hereditary non polyposis colon cancer). The recall the diagnostic criteria of HNPCC syndrome and emphasize the importance of guiding the clinical interview of patients with upper urinary tract tumours in order to detect a family history and the presence of gastrointestinal tumours.
2234. [Biomodulation and radiotherapy].
Recent improvement in the understanding of the mechanisms involved in the response to ionizing radiation have made it possible to identify new therapeutic targets to increase the anti-tumor efficacy or, alternatively, to decrease the effect on normal tissues. These approaches included targeting genes involved in the regulation of radio-induced DNA-repair and cell death as well as genes involved in the regulation of radio-induced apoptosis. Many other molecular targets have been recently identified to potentially interfere with the response to ionizing radiation, such as some cell membrane growth factor receptors (EGFr, TGFb) or molecules involved in intra-cellular signal transduction pathways, cell cycle regulation, etc. In addition, other promising ways to modulate radiation-induced response concern extracellular or tissue factors such as hypoxia and angiogenesis.
2235. [File no. 40. DNA polymerase n (Pol H) in hRad30A. Repair gene].2236. [Telomere anomalies, chromosome reshaping and cancer: an explanatory model of the formation of carcinomas].2237. [BRCA1 and cancer: a new lead].2238. [Record no. 38: TGFBR2 (type II TGFbeta receptor)].2239. [New pharmacology techniques and methods in oncology].2240. [Methods for the preclinical screening of new anticancer agents]. |